Author

Anna Louise Beckett

AstraZeneca (United Kingdom)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alaide MorcavalloiD· 1 shared Anna Dominika StaniszewskaiD· 1 shared Elsa IrvingiD· 1 shared Jekaterina Vohhodina-TretjakovaiD· 1 shared Jennifer I. MossiD· 1 shared Josep V. FormentiD· 1 shared Michael P. Jacques· 1 shared Paul W.G. WijnhoveniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alaide MorcavalloORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

An inducible BRCA1 expression system with in vivo applicability uncovers activity of the combination of ATR and PARP inhibitors to overcome therapy resistance

Elsa Irving, Alaide Morcavallo, Jekaterina Vohhodina-Tretjakova, Paul W.G. Wijnhoven, Anna Louise Beckett, Michael P. Jacques, Rachel S Evans, Jennifer I. Moss, Anna Dominika Staniszewska, Josep V. Forment

This paper develops an inducible BRCA1 expression system to study hypomorphic variants and finds that combining ATR and PARP inhibitors overcomes resistance caused by BRCA1 {Delta}exon11 hypomorphs.

Cancers · Jan 20, 2026Peer-reviewedCancer Biology